ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (ACTU)
CUSIP: 005083100
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 23,165,208
- Total 13F shares
- 11,217,203
- Share change
- +814,706
- Total reported value
- $68,541,901
- Price per share
- $6.11
- Number of holders
- 38
- Value change
- +$4,868,272
- Number of buys
- 32
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 005083100?
CUSIP 005083100 identifies ACTU - ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 005083100:
Top shareholders of ACTU - ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BIOS Fund I, LP |
13D/G
|
AARON G.L. FLETCHER |
50%
|
10,267,232
|
$112,734,207 | +$1,733,259 | 27 Jun 2025 | |
| Aaron G.l. Fletcher |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
10,329,768
mixed-class rows
|
$111,175,297 | +$499,996 | 27 Jun 2025 | |
| Bios Equity COF, LP |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
10,314,768
mixed-class rows
|
$111,175,297 | +$499,996 | 27 Jun 2025 | |
| Leslie W. Kreis |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
10,314,768
mixed-class rows
|
$111,175,297 | +$499,996 | 27 Jun 2025 | |
| BIOS Capital Management, LP |
13F
|
Company |
43%
|
9,893,651
|
$66,980,018 | — | 31 Mar 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.61%
|
142,381
|
$963,919 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.23%
|
53,852
|
$364,578 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
47,634
|
$322,482 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.14%
|
33,489
|
$226,720 | — | 31 Mar 2025 | |
| NORTHWESTERN UNIVERSITY |
13F
|
Company |
0.12%
|
27,778
|
$188,056 | — | 31 Mar 2025 | |
| Sigma Planning Corp |
13F
|
Company |
0.1%
|
23,675
|
$160,280 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.1%
|
22,358
|
$151,364 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.08%
|
18,538
|
$126,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.08%
|
18,574
|
$125,746 | — | 31 Mar 2025 | |
| MERCER GLOBAL ADVISORS INC /ADV |
13F
|
Company |
0.07%
|
16,344
|
$110,649 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.07%
|
16,114
|
$109,092 | — | 31 Mar 2025 | |
| Chicago Partners Investment Group LLC |
13F
|
Company |
0.04%
|
10,365
|
$96,395 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.06%
|
14,185
|
$96,032 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.05%
|
12,185
|
$82,492 | — | 31 Mar 2025 | |
| KG&L Capital Management,LLC |
13F
|
Company |
0.05%
|
12,000
|
$81,240 | — | 31 Mar 2025 | |
| SFMG, LLC |
13F
|
Company |
0.05%
|
11,000
|
$74,470 | — | 31 Mar 2025 | |
| Freestone Capital Holdings, LLC |
13F
|
Company |
0.04%
|
10,000
|
$67,700 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.03%
|
7,598
|
$51,438 | — | 31 Mar 2025 | |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO |
13F
|
Company |
0.01%
|
3,125
|
$21,156 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
2,555
|
$17,297 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
1,979
|
$13,398 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,538
|
$10,413 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
649
|
$4,394 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
25
|
$169 | — | 31 Mar 2025 | |
| Bios Clinical Opportunity Fund, LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
231,377
|
— | — | 12 Aug 2024 | |
| Bios 2024 Co-Invest, LP |
3/4/5
|
Director, Member of 10% Group |
—
class O/S missing
|
125,000
|
— | — | 14 Aug 2024 | |
| Dan Zabrowski |
3/4/5
|
Director |
—
mixed-class rows
|
106,348
mixed-class rows
|
— | — | 22 May 2025 | |
| Amy L. Ronneberg |
3/4/5
|
Director |
—
mixed-class rows
|
45,000
mixed-class rows
|
— | — | 22 May 2025 | |
| Jason A. Keyes |
3/4/5
|
Director |
—
mixed-class rows
|
45,000
mixed-class rows
|
— | — | 22 May 2025 | |
| Roger Sawhney |
3/4/5
|
Director |
—
mixed-class rows
|
45,000
mixed-class rows
|
— | — | 22 May 2025 |
Institutional Holders of ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (ACTU) as of Q2 2025
As of 30 Jun 2025,
ACTUATE THERAPEUTICS, INC. - Common Stock, par value $0.0001 per share (ACTU) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,217,203 shares.
The largest 10 holders included
BIOS Capital Management, LP, Voss Capital, LP, VANGUARD GROUP INC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, BARCLAYS PLC, STATE STREET CORP, NORTHWESTERN UNIVERSITY, and Gleason Group, Inc..
This page lists
38
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
25
Q2 2025 holders
38
Holder diff
13
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.